A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia

TAK-063 is a potent, selective inhibitor of phosphodiesterase 10A, an enzyme selectively expressed in medium spiny neurons of the striatum. This randomized, parallel-group study evaluated the efficacy and safety of 20-mg daily TAK-063 versus placebo in subjects with acutely exacerbated symptoms of schizophrenia (NCT02477020).

Source: Schizophrenia Research - September 3, 2018 Category: Psychiatry Authors: Thomas A. Macek, Maggie McCue, Xinxin Dong, Elizabeth Hanson, Paul Goldsmith, John Affinito, Atul R. Mahableshwarkar Source Type: research